行情

ARAV

ARAV

Aravive Inc
NASDAQ

实时行情|Nasdaq Last Sale

8.35
+0.27
+3.34%
休市 16:00 09/20 EDT
开盘
7.77
昨收
8.08
最高
8.35
最低
7.77
成交量
9.88万
成交额
--
52周最高
9.60
52周最低
3.070
市值
9,422.94万
市盈率(TTM)
-1.2771
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ARAV 新闻

  • 股价迄今飙升超300% Roku投资者为何急跳墙?
  • 新浪财经-自媒体综合.2小时前
  • 美欧飞机补贴案恐再掀巨浪 WTO最早9月30日宣判
  • 新浪美股.2小时前
  • 亚马逊送货计划再升级 能否打造理想送货车队?
  • 新浪财经-自媒体综合.3小时前
  • 拼多多:iPhone 11系列手机销量同比增长20倍
  • 界面.5小时前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

ARAV 简况

Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.
展开

Webull提供Aravive Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。